- decreased locomotor activity / IMPC
- increased circulating alanine transaminase level / IMPC
- increased mean corpuscular hemoglobin / IMPC
- increased monocyte cell number / IMPC
- increased lean body mass / IMPC
- increased fasting circulating glucose level / IMPC
- increased circulating calcium level / IMPC
- decreased erythrocyte cell number / IMPC
- decreased respiratory quotient / IMPC
- increased fluid intake / IMPC
- decreased prepulse inhibition / IMPC
- increased food intake / IMPC
- decreased total body fat amount / IMPC
- short tibia / IMPC
- increased circulating alkaline phosphatase level / IMPC
- increased circulating cholesterol level / IMPC
- decreased body length / IMPC
- decreased bone mineral content / IMPC
- increased large unstained cell number / IMPC
- increased circulating phosphate level / IMPC
- increased cornea thickness / IMPC
- decreased total retina thickness / IMPC
- increased circulating HDL cholesterol level / IMPC
- increased circulating aspartate transaminase level / IMPC
- abnormal gait / IMPC
- abnormal bone structure / IMPC
- increased circulating total protein level / IMPC
- increased mean corpuscular volume / IMPC
- increased circulating serum albumin level / IMPC
- increased neutrophil cell number / IMPC
- improved glucose tolerance / IMPC
- increased circulating glucose level / IMPC
C57BL/6NTac-Bscl2em1(IMPC)H/H
Status | Available to order |
EMMA ID | EM:11506 |
International strain name | C57BL/6NTac-Bscl2em1(IMPC)H/H |
Alternative name | |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | Bscl2em1(IMPC)H |
Gene/Transgene symbol | Bscl2 |
Information from provider
Provider | MRC, Medical Research Council |
Provider affiliation | Mary Lyon Centre at MRC Harwell |
Genetic information | This mouse line originates from CRISPR zygote microinjection. For further details see the project page at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Animals used for archiving | heterozygous C57BL/6NTacUSA, heterozygous C57BL/6NTacUSA |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Berardinelli-Seip congenital lipodystrophy / Orphanet_528
- Distal hereditary motor neuropathy type 5 / Orphanet_139536
- Severe neurodegenerative syndrome with lipodystrophy / Orphanet_363400
- Autosomal dominant spastic paraplegia type 17 / Orphanet_100998
IMPC phenotypes (gene matching)
MGI phenotypes (gene matching)
- increased brown adipose tissue amount / MGI
- enlarged heart / MGI
- abnormal intestine morphology / MGI
- abnormal small intestine morphology / MGI
- enlarged liver / MGI
- enlarged spleen / MGI
- abnormal testis morphology / MGI
- abnormal spermatogenesis / MGI
- decreased body weight / MGI
- decreased body size / MGI
- polyphagia / MGI
- increased circulating triglyceride level / MGI
- increased circulating free fatty acid level / MGI
- increased circulating HDL cholesterol level / MGI
- hyperglycemia / MGI
- decreased brown adipose tissue amount / MGI
- abnormal white adipose tissue amount / MGI
- decreased white adipose tissue amount / MGI
- male infertility / MGI
- abnormal spermiogenesis / MGI
- abnormal glucose homeostasis / MGI
- increased circulating insulin level / MGI
- abnormal lipid homeostasis / MGI
- hepatic steatosis / MGI
- abnormal epididymis morphology / MGI
- decreased circulating triglyceride level / MGI
- asthenozoospermia / MGI
- oligozoospermia / MGI
- decreased circulating free fatty acid level / MGI
- abnormal white adipose tissue morphology / MGI
- increased liver weight / MGI
- no phenotypic analysis / MGI
- enlarged kidney / MGI
- decreased circulating glycerol level / MGI
- increased circulating glycerol level / MGI
- increased lean body mass / MGI
- abnormal phospholipid level / MGI
- decreased energy expenditure / MGI
- decreased adiponectin level / MGI
- increased circulating cholesterol level / MGI
- decreased oxygen consumption / MGI
- impaired glucose tolerance / MGI
- insulin resistance / MGI
- abnormal fat pad morphology / MGI
- liver/biliary system phenotype / MGI
- homeostasis/metabolism phenotype / MGI
- behavior/neurological phenotype / MGI
- increased body temperature / MGI
- increased circulating glucose level / MGI
- decreased circulating glucose level / MGI
- teratozoospermia / MGI
- decreased circulating leptin level / MGI
- abnormal white adipose tissue physiology / MGI
- abnormal epididymal fat pad morphology / MGI
- abnormal male germ cell morphology / MGI
- abnormal spermatid morphology / MGI
- enhanced lipolysis / MGI
- decreased subcutaneous adipose tissue amount / MGI
- abnormal sperm flagellum morphology / MGI
- decreased carbon dioxide production / MGI
- abnormal white fat cell morphology / MGI
- decreased white fat cell number / MGI
- decreased white fat cell size / MGI
- abnormal sperm head morphology / MGI
- decreased gonadal fat pad weight / MGI
- decreased inguinal fat pad weight / MGI
- decreased interscapular fat pad weight / MGI
- decreased mesenteric fat pad weight / MGI
- decreased renal fat pad weight / MGI
- decreased retroperitoneal fat pad weight / MGI
- increased liver triglyceride level / MGI
- decreased total body fat amount / MGI
- abnormal cellular respiration / MGI
- abnormal aerobic respiration / MGI
- postnatal lethality, incomplete penetrance / MGI
- preweaning lethality, incomplete penetrance / MGI
- abnormal hypodermis fat layer morphology / MGI
- abnormal adipose tissue development / MGI
- abnormal fat cell differentiation / MGI
- abnormal white fat cell differentation / MGI
- lipodystrophy / MGI
- increased food intake / MGI
- abnormal lipid metabolism / MGI
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).